CS060380
Phase 2Small molecule
CS060380 is one of 81 small molecule programs targeting Non-Alcoholic Steatohepatitis. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1Amidate
PfizerPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Adenocard
AstellasPreclinical
Activella
Eli LillyPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
CS060380
CCascade Pharmaceuticals, Inc
Phase 2
Spiriva
Boehringer IngelheimPreclinical
Flagyl
DDePuy Orthopaedics
Preclinical
Prometrium
FerringPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CS060380. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCascade Pharmaceuticals, Inc